Invention Grant
- Patent Title: Recombinant protein targeting PD-L1 and VEGF
-
Application No.: US16699732Application Date: 2019-12-02
-
Publication No.: US11407832B2Publication Date: 2022-08-09
- Inventor: Wenzhi Tian , Song Li
- Applicant: ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
- Applicant Address: CN Shanghai
- Assignee: ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
- Current Assignee: ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
- Current Assignee Address: CN Shanghai
- Agency: Duane Morris LLP
- Agent Thomas J. Kowalski; Deborah L. Lu
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; C07K14/71 ; A61K38/00 ; A61K39/00

Abstract:
Disclosed is a recombinant protein containing 1) an anti-PD-L1 antibody heavy chain and an anti-PD-L1 antibody light chain, which two are linked by a disulfide bond to bind PD-L1, and 2) an extracellular Ig-like domain of a vascular epithelial growth factor receptor (VEGFR), linked via a linker to the N-terminus or C-terminus of the heavy chain or the light chain, wherein the recombinant protein is capable of binding PD-L1, VEGF and Fc receptor simultaneously. Also disclosed are a recombinant antibody containing two recombinant proteins of the disclosure, a polynucleotide encoding the recombinant protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of VEGF and/or PD-L1 using the recombinant protein.
Public/Granted literature
- US20200172623A1 RECOMBINANT PROTEIN TARGETING PD-L1 AND VEGF Public/Granted day:2020-06-04
Information query